Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31

Elizabeth Tan-Chiu, Greg Yothers, Edward Romond, Charles E. Geyer, Michael Ewer, Deborah Keefe, Richard P. Shannon, Sandra M. Swain, Ann Brown, Louis Fehrenbacher, Victor G. Vogel, Thomas E. Seay, Priya Rastogi, Eleftherios P. Mamounas, Norman Wolmark, John Bryant

Research output: Contribution to journalArticlepeer-review

699 Scopus citations

Fingerprint

Dive into the research topics of 'Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31'. Together they form a unique fingerprint.

Medicine & Life Sciences